Omadacycline
- Generic Name
- Omadacycline
- Brand Names
- Nuzyra
- Drug Type
- Small Molecule
- Chemical Formula
- C29H40N4O7
- CAS Number
- 389139-89-3
- Unique Ingredient Identifier
- 090IP5RV8F
- Background
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly prob...
- Indication
Omadacycline is indicated for the treatment of community acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by omadacycline-susceptible organisms in adults.
- Associated Conditions
- Acute Bacterial Skin and Skin Structure Infection (ABSSSI), Community-Acquired Bacterial Pneumonia (CABP)
- Associated Therapies
- -
Zai Lab announces the inclusion of Augtyro for ROS1+ NSCLC and other updates in China's
Zai Lab announces NRDL inclusion of Augtyro for ROS1+ NSCLC, renewal of Nuzyra for CABP/ABSSSI, and Qinlock for GIST, expanding patient access to innovative treatments in China.
Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
Zai Lab reports Q3 2024 net product revenue growth of 47% y-o-y to $101.8M, positive China bridging study results for KarXT in schizophrenia, and global Phase 1 data suggesting best-in-class potential for ZL-1310 in extensive-stage SCLC. The company expects three product launches in China by end of 2024 and up to four NMPA regulatory submissions in the next six months. Cash position was $716.1M as of September 30, 2024.
Paratek's antibiotic succeeds in Phase IIb lung disease trial
Paratek's Nuzyra shows positive Phase IIb trial results for NTM pulmonary disease, with trends favoring omadacycline across primary and secondary endpoints. Nuzyra, approved by the FDA for CABP and ABSSSI, is expected to generate $119m by 2030.
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA
Paratek Pharmaceuticals to present NUZYRA data at IDWeek 2024, including interim safety results for bone and joint infections and real-world outcomes for pulmonary Mycobacterium abscessus complex.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath